XML 93 R83.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Liability Related to Sale of Future Revenues - Additional Information (Detail) - USD ($) |  |  | 12 Months Ended
--- | --- | --- | ---
Nov. 17, 2022 | Nov. 04, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Transaction costs related to sale of future revenues |  |  | $ 0 | $ 1,453,000 | $ 0
Total revenue |  |  | 147,752,000 | 140,734,000 | 235,309,000
Drug Product Revenue [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Total revenue |  |  | $ 18,753,000 | $ 11,086,000 | 962,000
NovaQuest Capital Management [Member] | Revenue Interest Financing Agreement [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Transaction costs related to sale of future revenues |  | $ 1,700,000 |  |  |
Effective annual interest rate related to sale of future revenues |  |  | 16.03% | 19.67% |
NovaQuest Capital Management [Member] | Payment Cap Date on or before December 31, 2028 [Member] | Revenue Interest Financing Agreement [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Maximum payment cap amount |  | 100,000,000 |  |  |
NovaQuest Capital Management [Member] | Payment Cap Date on or after January 1, 2029 [Member] | Revenue Interest Financing Agreement [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Maximum payment cap amount |  | 112,500,000 |  |  |
NovaQuest Capital Management [Member] | Payment Cap Date after January 1, 2030 [Member] | Revenue Interest Financing Agreement [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Maximum payment cap amount |  | 125,000,000 |  |  |
Minimum [Member] | NovaQuest Capital Management [Member] | Revenue Interest Financing Agreement [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Prepayment amount of 2024 to 2030 |  | 80,000,000 |  |  |
Minimum [Member] | NovaQuest Capital Management [Member] | Payment Period One [Member] | Revenue Interest Financing Agreement [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Revenue interest payment |  | 62,500,000 |  |  |
Minimum [Member] | NovaQuest Capital Management [Member] | Payment Period Two [Member] | Revenue Interest Financing Agreement [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Revenue interest payment |  | 125,000,000 |  |  |
Maximum [Member] | NovaQuest Capital Management [Member] | Revenue Interest Financing Agreement [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Prepayment amount of 2024 to 2030 |  | 125,000,000 |  |  |
Product [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Total revenue |  |  | $ 100,949,000 | $ 82,869,000 | 47,638,000
Product [Member] | NovaQuest Capital Management [Member] | Revenue Interest Financing Agreement [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Revenue interest payment |  | 10,000,000 |  |  |
License [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Total revenue |  |  | 9,649,000 | 22,590,000 | 116,434,000
Other Revenue - Contract Manufacturing [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Total revenue |  |  | 18,401,000 | 24,189,000 | $ 70,275,000
Astellas Agreement [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Future revenue granted |  | $ 50,000,000 |  |  |
Percentage of revenue interest on global net sales |  | 100.00% |  |  |
Received from sale of revenue | $ 49,800,000 |  |  |  |
Gross proceeds received from sale of revenue | $ 50,000,000 |  |  |  |
Astellas Agreement [Member] | Regulatory Milestone [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Total revenue |  |  |  | 25,000,000 |
Astellas Agreement [Member] | Drug Product Revenue [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Total revenue |  |  | 18,800,000 | 11,100,000 |
Non-cash interest expense related to drug product revenue |  |  | $ 7,700,000 | 1,000,000 |
Astellas Agreement [Member] | Development Revenue [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Total revenue |  |  |  | 2,400,000 |
Astellas Agreement [Member] | Maximum [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Revenue payment cap amount |  |  |  | 125,000,000 |
Astellas Agreement [Member] | Product [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Percentage of revenue sold |  | 22.50% |  |  |
Astellas Agreement [Member] | Milestone payments [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Percentage of revenue sold |  | 10.00% |  |  |
Astellas Agreement [Member] | Milestone payments [Member] | Payment Period One [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Percentage of revenue sold |  | 20.00% |  |  |
Astellas Agreement [Member] | License [Member] |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Total revenue |  |  |  | $ 22,600,000 |

X
- Definition Effective Annual Interest Rate Related To Sale Of Future Revenues + References No definition available. + Details
Name: | fgen_EffectiveAnnualInterestRateRelatedToSaleOfFutureRevenues
Namespace Prefix: | fgen_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Future revenue granted. + References No definition available. + Details
Name: | fgen_FutureRevenueGranted
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Gross proceeds received from sale of revenue. + References No definition available. + Details
Name: | fgen_GrossProceedsReceivedFromSaleOfRevenue
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum payment cap amount. + References No definition available. + Details
Name: | fgen_MaximumPaymentCapAmount
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non-cash interest expense related to drug product revenue + References No definition available. + Details
Name: | fgen_NonCashInterestExpenseRelatedToDrugProductRevenue
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payments for transaction costs related to sale of future revenues. + References No definition available. + Details
Name: | fgen_PaymentsForTransactionCostsRelatedToSaleOfFutureRevenues
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of revenue interest on global net sales. + References No definition available. + Details
Name: | fgen_PercentageOfRevenueInterestOnGlobalNetSales
Namespace Prefix: | fgen_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of revenue sold. + References No definition available. + Details
Name: | fgen_PercentageOfRevenueSold
Namespace Prefix: | fgen_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Prepayment amount. + References No definition available. + Details
Name: | fgen_PrepaymentAmount
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Received from sale of revenue. + References No definition available. + Details
Name: | fgen_ReceivedFromSaleOfRevenue
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Revenue interest payment. + References No definition available. + Details
Name: | fgen_RevenueInterestPayment
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Revenue payment cap amount. + References No definition available. + Details
Name: | fgen_RevenuePaymentCapAmount
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=fgen_NovaquestCapitalManagementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=fgen_RevenueInterestFinancingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardDateAxis=fgen_PaymentCapDateOnOrBeforeDecemberThirtyOneTwoThousandTwentyEightMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardDateAxis=fgen_PaymentCapDateOnOrAfterJanuaryOneTwoThousandTwentyNineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardDateAxis=fgen_PaymentCapDateAfterJanuaryOneTwoThousandThirtyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardDateAxis=fgen_PaymentPeriodOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardDateAxis=fgen_PaymentPeriodTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=fgen_DevelopmentAndOtherRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fgen_AstellasAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_RegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DevelopmentRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=fgen_MilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |